492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers
David M. O’Malley(The Ohio State University), Antonio Jimeno(University of Colorado Cancer Center), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute), Anjali Desai(Breast Center), Rana Fiaz(Integrated BioTherapeutics (United States)), Robert M. Wenham(Moffitt Cancer Center), Antonio Reuda(Hospital Regional Universitario de Málaga), Amanda Psyrri(National and Kapodistrian University of Athens), Sajeve Thomas(Orlando Health), Madan Jagasia(Vanderbilt University Medical Center), Bradley Monk(The US Oncology Network), Brigid Garelik(Theravance Biopharma (United States)), Helen Gogas(National and Kapodistrian University of Athens), Sylvia Lee(University of Washington), Guang Chen(Theravance Biopharma (United States)), Wen Shi(Theravance Biopharma (United States)), Friedrich Graf Finckenstein(Integrated BioTherapeutics (United States)), Xiao Wu(Theravance Biopharma (United States)), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Giri Sulur(Theravance Biopharma (United States)), Peter G. Rose(Cleveland Clinic)
Cited by 37
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k